share_log

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target

HC Wainwright & Co.重申买入 Regulus Therapeutics,维持9美元的目标股价
Benzinga ·  2023/09/19 06:13

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9 price target.

HC Wainwright&Co.分析师Raghuram Selvaraju重申Regulus Treateutics(纳斯达克:RGLS)的买入,并维持9美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发